10x Genomics $TXG Shares Bought by Ieq Capital LLC

Key Points

• Ieq Capital LLC increased its stake in 10x Genomics by 80.4%, owning 285,298 shares valued at approximately $2.49 million.
• Recent sales by insiders included Benjamin J. Hindson selling 7,486 shares and CFO Adam Taich selling 22,315 shares, both on August 22nd, decreasing their positions by 1.67% and 6.73%, respectively.
• The stock's **52-week** range shows a low of $6.78 and a high of $24.76, with a current market cap of **$1.74 billion**.

Ieq Capital LLC increased its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 80.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 285,298 shares of the company's stock after buying an additional 127,186 shares during the period. Ieq Capital LLC owned about 0.23% of 10x Genomics worth $2,491,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Jump Financial LLC increased its stake in shares of 10x Genomics by 144.3% in the first quarter. Jump Financial LLC now owns 452,282 shares of the company's stock worth $3,948,000 after buying an additional 267,181 shares during the last quarter. AlphaQuest LLC raised its stake in 10x Genomics by 8.3% during the first quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock valued at $257,000 after buying an additional 2,258 shares in the last quarter. EntryPoint Capital LLC bought a new position in 10x Genomics during the 1st quarter worth approximately $420,000. Fox Run Management L.L.C. bought a new position in 10x Genomics during the 1st quarter worth approximately $270,000. Finally, Russell Investments Group Ltd. lifted its holdings in 10x Genomics by 385.6% during the 1st quarter. Russell Investments Group Ltd. now owns 81,669 shares of the company's stock worth $713,000 after buying an additional 64,851 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. Company insiders own 10.03% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on TXG. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the stock a "hold" rating in a report on Friday, August 8th. JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, August 30th. UBS Group lifted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, Barclays reaffirmed an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $13.54.

10x Genomics Trading Up 0.6%

TXG traded up $0.09 during trading hours on Thursday, hitting $13.43. The company's stock had a trading volume of 718,366 shares, compared to its average volume of 3,353,427. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.38. The firm has a market capitalization of $1.67 billion, a PE ratio of -19.19 and a beta of 2.00. The company has a 50-day simple moving average of $13.07 and a 200 day simple moving average of $10.73.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. During the same period last year, the firm earned ($0.32) EPS. The firm's revenue was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. Research analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.